ENPP1 is an innate immune checkpoint of the anticancer cGAMP–STING pathway in breast cancer
Proceedings of the National Academy of Sciences · 26.12.2023 · 120 (52)
DOI: 10.1073/pnas.2313693120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 20.12.2023. Verfasst von Songnan Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Stanford University, Stanford, CA 94305. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 97-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, HHS | NIH | National Cancer Institute.
Abstract (Originalsprache)
Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) expression correlates with poor prognosis in many cancers, and we previously discovered that ENPP1 is the dominant hydrolase of extracellular cGAMP: a cancer-cell-produced immunotransmitter that activates the anticancer stimulator of interferon genes (STING) pathway. However, ENPP1 has other catalytic activities and the molecular and cellular mechanisms contributing to its tumorigenic effects remain unclear. Here, using single-cell RNA-seq, we show that ENPP1 in both cancer and normal tissues drives primary breast tumor growth and metastasis by dampening extracellular 2′3′-cyclic-GMP-AMP (cGAMP)–STING-mediated antitumoral immunity. ENPP1 loss-of-function in both cancer cells and normal tissues slowed primary tumor growth and abolished metastasis. Selectively abolishing the cGAMP hydrolysis activity of ENPP1 phenocopied ENPP1 knockout in a STING-dependent manner, demonstrating that restoration of paracrine cGAMP–STING signaling is the dominant anti-cancer mechanism of ENPP1 inhibition. Finally, ENPP1 expression in breast tumors deterministically predicated whether patients would remain free of distant metastasis after pembrolizumab (anti-PD-1) treatment followed by surgery. Altogether, ENPP1 blockade represents a strategy to exploit cancer-produced extracellular cGAMP for controlled local activation of STING and is therefore a promising therapeutic approach against breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Stanford University, Stanford, CA 94305.
- ChEM-H Institute, Stanford University, Stanford, CA 94305.
- Arc Institute, Palo Alto, CA 94304.
- Department of Urology, University of California, San Francisco, CA 94143.
- Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94158.
- Department of Biophysics & Biochemistry, University of California, San Francisco, CA 94143.
ORCID-Profile: Songnan Wang, Alby J Joseph, Valentino Sudaryo, Feiqiao B Yu, Vishvak Subramanyam, Xuchao Lyu, Hani Goodarzi, Lingyin Li
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- HHS | NIH | National Cancer Institute
- Era of Hope Scholar
- Breast Cancer Research Foundation
Zitieren
APA
Wang, S., Böhnert, V., Joseph, A. J., Sudaryo, V., Skariah, G., Swinderman, J. T., Yu, F. B., Subramanyam, V., Wolf, D. M., Lyu, X., Gilbert, L. A., Van't Veer, L. J., Goodarzi, H., & Li, L. (2023). ENPP1 is an innate immune checkpoint of the anticancer cGAMP–STING pathway in breast cancer. Proceedings of the National Academy of Sciences, 120(52). https://doi.org/10.1073/pnas.2313693120
Vancouver
Wang S, Böhnert V, Joseph AJ, Sudaryo V, Skariah G, Swinderman JT, et al. ENPP1 is an innate immune checkpoint of the anticancer cGAMP–STING pathway in breast cancer. Proceedings of the National Academy of Sciences. 2023;120(52). doi:10.1073/pnas.2313693120
BibTeX
@article{Wang2023,
author = {Wang, Songnan and Böhnert, Volker and Joseph, Alby J and Sudaryo, Valentino and Skariah, Gemini and Swinderman, Jason T and Yu, Feiqiao B and Subramanyam, Vishvak and Wolf, Denise M and Lyu, Xuchao and Gilbert, Luke A and Van't Veer, Laura J and Goodarzi, Hani and Li, Lingyin},
title = {ENPP1 is an innate immune checkpoint of the anticancer cGAMP–STING pathway in breast cancer},
journal = {Proceedings of the National Academy of Sciences},
year = {2023},
volume = {120},
number = {52},
doi = {10.1073/pnas.2313693120}
}
EUVIMED